Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Rises By 231.4%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 16,141 shares, a growth of 231.4% from the January 15th total of 4,870 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily volume of 34,180 shares, the short-interest ratio is currently 0.5 days. Based on an average daily volume of 34,180 shares, the short-interest ratio is currently 0.5 days. Currently, 0.8% of the company’s stock are sold short.

Xenetic Biosciences Stock Up 0.5%

Shares of NASDAQ:XBIO opened at $2.14 on Thursday. The firm has a market capitalization of $4.90 million, a PE ratio of -1.04 and a beta of 2.29. The company has a 50-day moving average price of $2.27 and a two-hundred day moving average price of $2.95. Xenetic Biosciences has a twelve month low of $1.90 and a twelve month high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.16. Xenetic Biosciences had a negative net margin of 110.42% and a negative return on equity of 64.66%. The company had revenue of $1.03 million during the quarter. Analysts anticipate that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce”.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.